The Molecular Epidemiology of Lung Cancer

References

• US Dept. HHS. Public Health Service, L. A. Gloeckler-Ries. NIH, NCI, Bethesda, MD 1973 to 88, Publication 91–2789. Cancer Statistics Review
   Google Scholar
• Shaw G. L., Falk R. T., Pickle L. W., Mason T. J., Buffler P. A. Lung cancer risk associated with cancer in relatives. J. Clin. Epidemiol. 1991; 44: 429
   PubMed Web of Science ®Google Scholar
• Osann K. E. Lung cancer in women: the importance of smoking, family history of cancer, and medical history of respiratory disease. Cancer Res. 1991; 51: 4893
   PubMed Web of Science ®Google Scholar
• McDuffie H. H. Clustering of cancer in families of patients with primary lung cancer. J. Clin. Epidemiol. 1991; 44: 69
   PubMed Web of Science ®Google Scholar
• Ooi W. L., Elston R. C., Chen V. W., Bailey-Wilson J. E., Rothschild H. Increased familial risk for lung cancer. JNCI 1986; 2: 217
   Google Scholar
• Sellers T. A., Elston R. C., Stewart C., Rothschild H. Familial risk of cancer among randomly selected cancer probands. Genet. Epidemiol. 1988; 5: 381
   PubMed Web of Science ®Google Scholar
• Liu Z., He X., Chapman R. S. Smoking and other risk factors for lung cancer in Xuanwei, China. Int. J. Epidemiol. 1991; 21: 26
   Google Scholar
• Samet J. M., Humble C. G., Pathak D. R. Personal and family history of respiratory disease and lung cancer risk. Am. Rev. Respir. Dis. 1986; 134: 466
   PubMedGoogle Scholar
• Braun M. M., Caporaso N. E., Page W. F., Hoover R. N. Genetic component of lung cancer: cohort study of twins. Lancet 1994; 344: 440
   PubMedGoogle Scholar
• Braun M. M., Caporaso N. E., Page W. F., Hoover R. N. A cohort study of twins and cancer. Cancer Epidemiol. Biomark. Prev. 1995; 4: 469
   PubMedGoogle Scholar
• Olsen J. H., Boice J. D., Seersholm N., Bautz A., Fraumeni J. F. Cancer in the parents of children with cancer. N. Engl. J. Med. 1995; 333: 1594
   PubMedGoogle Scholar
• Sorensen T. I. A. Is there an inherited general susceptibility to cancer. N. Engl. J. Med. 1995; 333: 1633
   PubMedGoogle Scholar
• Mulshine J. L., Linnoila R. I., Jensen S. M., Magnani J. L., Tockman M. S., Gupta P. K., Scott F. S., Avis I., Quinn K., Birrer M. J. Rational targets for the early detection of lung cancer. Monographs—National Cancer Institute 1992; 13: 183
   Google Scholar
• Tockman M. S., Gupta P. K., Pressman N. J., Mulshine J. L. Cytometric validation of immunocytochemical observations in developing lung cancer. Diagn. Cytopathol. 1993; 9(6)615
   PubMedGoogle Scholar
• Mao L., Lee D. J., Tockman M. S., Erozan Y. S., Askin F., Sidransky D. Microsatellite alterations as clonal markers for the detection of human cancer. Proc. Natl. Acad. Sci. U.S.A. 1994; 91(21)9871
   PubMedGoogle Scholar
• Perera F. Molecular cancer epidemiology: a new tool in cancer prevention. JNCI 1987; 78: 887
   PubMed Web of Science ®Google Scholar
• Ware J., Neumann D. On repeated measures, Personal communication. Harvard SPH, 8/9/96
   Google Scholar
• Wyllie A. H. Apoptosis. Br. J. Cancer 1993; 67: 205
   PubMed Web of Science ®Google Scholar
• Robbins S. L., Cotran R. S., Kumar V. The Pathologic Basis of Disease, 4th ed. Saunders, Philadelphia 1989
   Google Scholar
• Jacobson D. R., Fishman C. L., Mills N. E. Molecular genetic tumor markers in the early diagnosis and screening of non-small lung cancer. Ann. Oncol 1995; 6(Suppl. 3)S3
   Google Scholar
• Idle J. R. Is environmental carcinogenesis modulated by host polymorphism. Mutat Res. 1991; 247: 259
   PubMedGoogle Scholar
• Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. TheCYP1A1 gene and cancer susceptibility. Crit. Rev. Oncol. Hematol. 1993; 14: 77
   PubMed Web of Science ®Google Scholar
• Guengerich F. P. Roles of cytochrome P-450 enzymes in chemical carcinogenesis and cancer chemotherapy. Cancer Res. 1988; 48: 2946
   PubMed Web of Science ®Google Scholar
• Wheeler C. W., Guenther T. M. Cytochrome P450-dependent metabolism of xenobiotics in human lung. J. Biochem. Toxicol. 1991; 6: 163
   PubMedGoogle Scholar
• Amos C. J., Caporaso N. E., Western A. Host factors in lung cancer risk: a review of interdisciplinary studies. Cancer Epidemiol. Biomarkers Prevention 1992; 1: 505
   PubMed Web of Science ®Google Scholar
• Swanson H. I., Bradfield C. A. The Ah receptor, genetics, structure and function. Pharmacogenetics 1993; 3: 213
   PubMedGoogle Scholar
• Hayashi S., Watanabe J., Nakachi K., Eguchi H., Gotoh O., Kawajiri K. Interindividual difference in expression of human Ahr and related P450 genes. Carcinogenesis 1994; 15: 801
   PubMedGoogle Scholar
• Itoh S., Kamataki T. Human Ah receptor cDNA: analysis for highly conserved sequences. Nucl. Acids Res. 1993; 21: 3578
   PubMed Web of Science ®Google Scholar
• Fujii-Kuriyama Y., Ema M., Mimura J., Matsushita N., Sogawa K. Polymorphic forms of the Ah receptor and induction of the CYP1A1 gene. Pharmacogenetics 1995; 5: S149
   Google Scholar
• Kawajiri K., Watanabe J., Eguchi H., Nakachi K., Kiyohara C., Hayashi S. Polymorphisms of humanAh receptor gene are not involved in lung cancer. Pharmacogenetics 1995; 5: 151
   PubMedGoogle Scholar
• Miller E. C., Miller J. A. Search for ultimate chemical carcinogens and their reactions with cellular macromolecules. Cancer 1981; 47: 2327
   PubMed Web of Science ®Google Scholar
• Devereux T. R., Domin B. A., Philpot R. M. Xenobiotic metabolism by isolated pulmonary cells. Pharmacol. Ther. 1989; 41: 243
   PubMed Web of Science ®Google Scholar
• Jeffrey A. M., Weinstein I. B., Jennette K. W., Grzeskowiak K., Nakanishi K., Harvey R. G., Autrup H., Harris C. Structures of benzo[a]pyrene-nucleic acid adducts formed in human and bovine bronchial explants. Nature 1977; 269: 348
   PubMed Web of Science ®Google Scholar
• Karki N. T. Pokels, Neutice R.L., Pekonen O. Arylhydrocarbon hydroxylase in lymphocytes and lung tissue from lung cancer patients and controls. Int. J. Cancer 1987; 39: 565
   PubMed Web of Science ®Google Scholar
• Devereux T. R., Massey, VanScott T. E.M. R., Yankaskas J., Fouts J. R. Xenobiotic metabolism in human alveolar type II cells isolated by centrifuged elutriation, density gradient centrifugation. Cancer Res. 1986; 46: 5438
   PubMedGoogle Scholar
• Harris C. C., Autrup H., Connor R. D., Barrett L. A., McDowell E. M., Trump B. F. Interindividual variation in binding of benzo[a]pyrene to DNA in cultured human bronchi. Science 1976; 194: 1067
   PubMed Web of Science ®Google Scholar
• Wheeler C. W., Park S. S., Guenthner T. M. Immunochemical analysis of a cytochrome P-450IA1 homologue in human lung microsomes. Mol. Pharmacol. 1990; 38: 634
   PubMed Web of Science ®Google Scholar
• Rojas M., Camus A. M., Alexandrov K., Husgafvel-Pursiainen. Stereoselective metabolism of (-) benzo[a]-pyrene-7,8-diol by human lung microsomes and peripheral blood lymphocytes: effect of smoking. Carcinogenesis 1992; 13(6): 929
   Google Scholar
• Fasco M. J., Treanor C. P., Spivack S., Figge H., Kaminsky L. S. Quantitative RNA-polymerase chain reaction-DNA analysis by capillary electrophoresis and laser-induced fluorescence. Anal. Biochem. 1995; 224: 140
   PubMed Web of Science ®Google Scholar
• Nakajima T., Elovaara E., Anttila S., Hirvonen A., Camus A. M., Hayes J. D., Ketterer B., Vainio H. Expression and polymorphism of glutathioneS-transferase in human lungs: risk factors in smoking-related lung cancer. Carcinogenesis 1995; 16(4): 707
   Google Scholar
• Roberts E. A., Goles C. K., Okey A. B. Ah receptor mediating induction of AHH; detection in human lung by binding of 2,3,7,8-3H-tetrachlorodibenzo-p-dioxin. Cancer Res. 1986; 46: 3739
   PubMed Web of Science ®Google Scholar
• Cantrell E. T., Parr G. A., Buebic D. C., Martin R. R. Induction of AHH human pulmonary alvelor macrophages by cigarette smoke. J. Clin. Invest. 1973; 52: 1881
   PubMed Web of Science ®Google Scholar
• Kellerman G., Shaw C. R., Lufer-Kellerman M. AHH inducibility and bronchogenic carcinoma. N. Engl. J. Med. 1973; 289: 93
   Google Scholar
• Kouri R. E., McKinney C. E., Slomiany D. J., Snodgrass D. R., Wray N. P., McLemore T. L. Positive correlation between high AHH activity and primary lung cancer as analyzed in cryopreserved lymphocytes. Cancer Res. 1982; 42: 5030
   PubMed Web of Science ®Google Scholar
• Petruzelli S., Camus A. M., Carrozzi L., Ghelarducci L., Rindi M., Menconi G., Angeletti C. A., Ahotupa M., Hietanen E., Aitio A. Long-lasting effects of tobacco smoking on pulmonary drug and metabolizing enzymes: a case-control study on lung cancer patients. Cancer Res. 1988; 48: 4695
   PubMedGoogle Scholar
• Bartsch H., Petruzzelli S., DeFlora S. Carcinogen metabolism in human lung tissues and the effect of tobacco smoking. Environ. Health Persp. 1992; 4(98)119
   Google Scholar
• Kouri R. E., Billups L. H., Rude T. H., Whitmire C. E., Sass B., Henry C. J. Correlation of inducibility of AHH with susceptibility to 3-methycholanthrene-induced lung cancers. Cancer Lett. 1980; 9: 277
   PubMed Web of Science ®Google Scholar
• Kouri R. E., McKinney C. E., Levine A. S., Edwards B. K., Vesell E. S., Nebert D. W., McLemore T. L. Variations in AHH activities in mitogen-activated human and nonhuman primate lymphocyte. Toxicol. Pathol. 1984; 12: 44
   PubMedGoogle Scholar
• Omiecinski C. J., Redlich C. A., Costa P. Induction and developmental expression of cytochrome P450IA1 messenger RNA in rat and human tissues: detection by the polymerase chain reaction. Cancer Res. 1990; 50: 4315
   PubMed Web of Science ®Google Scholar
• McLemore T. L., Adelberg S., Liu M. C., McMahon N. A., Yu S. J., Hubbard W. C., Czerwinski M., Wood T. G., Storeng R., Lubet R. A. Expression of CYP1A1 gene in patients with lung cancer. J. Natl. Cancer Inst. 1990; 82: 1333
   PubMed Web of Science ®Google Scholar
• Cosma G. N., Toniolo P., Currie D., Pasternack B. S., Garte S. J. Expression of CYP1Al gene in peripheral lymphocytes as a marker of exposure to creosote in railroad workers. Cancer Epid. Biom. Prev. 1992; 1: 137
   PubMedGoogle Scholar
• Vanden Heuvel J. P., Clark G. C., Thompson C. L. CYP1A1 mRNA levels as a human exposure biomarker: use of quantitative RT-PCR to measure CYP1A1 expression in human peripheral blood lymphocytes. Carcinogenesis 1993; 1: 2003
   Google Scholar
• Petersen D. D., McKinney C. E., Ikeya K., Smith H. H., Bale A. E., McBride O. W., Nebert D. W. Human CYP1A1 gene: co-segregation of the enzyme inducibility phenotype and an RFLP. Am. J. Hum. Genet. 1991; 48: 720
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Nakachi K., Imai K., Yoshii A., Shinoda N., Watanabe J. Identification of genetically high-risk individuals to lung cancer by DNA polymorphisms of the cytochrome P450IA1 gene. FEBS Lett. 1990; 263: 131
   PubMed Web of Science ®Google Scholar
• Cosma G., Crofts F., Currie D., Wirgin I., Toniolo P., Garte S. J. Racial differences in RFLPs and mRNA inducibility of the human CYP1A1 gene. Cancer Epidemiol. Biomed. Prev. 1993; 3: 53
   Google Scholar
• Crofts F., Taioli E., Trachman J., Cosma G. N., Currie D., Toniolo P., Garte S. J. Functional significance of different human CYP1A1 genotypes. Carcinogenesis 1994; 15: 2961
   PubMed Web of Science ®Google Scholar
• Landi M. T., Bertazzi P. A., Shields P. G., Clark G., Lucier G. W., Garte S. J., Cosma G., Caporaso N. E. Association betweenCYP1A1 genotype, mRNA expression and enzymatic activity in humans. Pharmacogenetics 1994; 4: 242
   PubMedGoogle Scholar
• Kawamoto T., Koga M., Murata K., Matsuda S., Kodama Y. Effects of ALDH2, CYP1A1, and CYP2E1 genetic polymorphisms and smoking and drinking habits on toluene metabolism in humans. Tox. Appl. Pharmacol. 1995; 133: 295
   PubMed Web of Science ®Google Scholar
• Hayashi S., Watanabe J., Nakachi K., Kawajiri K. Genetic linkage of lung cancer-associatedMspI polymorphisms with amino acid replacement in the heme binding region of the human cytochrome P450IA1 gene. J. Biochem.(Tokyo) 1991; 110: 407
   PubMed Web of Science ®Google Scholar
• Hayashi S., Watanabe J., Kawajiri K. High susceptibility to lung cancer analyzed in terms of combined genotypes of P4501A1 and mu-class glutathioneS-tranferase genes. Jpn. J. Cancer Res. 1992; 83: 866
   PubMedGoogle Scholar
• Sugimura H., Suzuki I., Hamada G. S., Iwase T., Takahashi T., Nagura K., Iwata H., Watanabe S., Kino I., Tsugane S. Cytochrome P450IA1 genotype in lung cancer patients and controls in Rio de Janeiro, Brazil. Cancer Epidemiol. Biomed. Prev. 1994; 3: 145
   PubMedGoogle Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Karjalainen A., Anttila S., Vainio H. Point-mutational Mspl and Ile-Val polymorphisms closely linked in the CYP1A1 gene: lack of association with susceptibility to lung cancer in a Finnish study population. Cancer Epidemiol. Biomarkers Prev. 1992; 1: 485
   PubMed Web of Science ®Google Scholar
• Drakoulis N., Cascorbi I., Brockmoller J., Gross C. R., Roots I. Polymorphisms in the human CYP1A1 gene as a susceptibility factor for lung cancer. Clin. Invest. 1994; 72: 240
   PubMedGoogle Scholar
• Shields P. G., Caporaso N. E., Falk R. T., Sugimura H., Trivers G. E., Trump B. F., Hoover R. N., Weston A., Harris C. C. Lung cancer, race, and a CYP1Al genetic polymorphism. Cancer Epidem. Biomarkers Prev. 1993; 2: 481
   PubMed Web of Science ®Google Scholar
• Tefre T., Ryberg D., Haugen A., Nebert D. W., Skaug V., Brogger A., Borresen A. L. Human CYP1A1 gene: lack of association between the MSPI restriction fragment length polymorphisms and incidence of lung cancer in a Norwegian population. Pharmacogenetics 1991; 1: 20
   PubMedGoogle Scholar
• Shields P. G., Bowman E. D., Harrington A. M. Polycycle aromatic hydrocarbon DNA adducts in human lung and cancer susceptiblity genes. Cancer Res. 1993; 53: 3486
   PubMed Web of Science ®Google Scholar
• Hamada G. S., Sugimura H., Suzuki I., Nagura K., Kiyokawa E., Iwase T., Tanaka M., Takahashi T., Watanable S., Kino I. The heme-binding region ofCYP1A1, rather than the Rsa polymorphism ofCYP2E1, is associated with lung cancer in Rio de Janeiro. Cancer Epid. Biom. Prev. 1995; 4: 63
   PubMedGoogle Scholar
• London S. J., Daly A. J., Fairbrother K. S., Holmes C., Carpenter C. L., Navidi W. C., Idle J. R. Lung cancer risk in African-Americans in relation to a race-specificCYP1A1 polymorphism. Cancer Res. 1995; 55: 6035
   PubMed Web of Science ®Google Scholar
• Taoli E., Crofts F., Trachman J., Demopoulos R., Toniolo P., Garte S. J. A specific African-AmericanCYP1A1 polymorphism is associated with adenocarcinoma of the lung. Cancer Res. 1995; 55: 472
   PubMedGoogle Scholar
• Gonzalez F. J., Gelboin H. V. Role of human cytochromes P450 in the metabolic activation of chemical carcinogens and toxins. Drug Metab. Rev. 1994; 26: 165
   PubMed Web of Science ®Google Scholar
• Smith C. A. D., Moss J. E., Gough A. C. Molecular genetic analysis of the cytochrome P450-debrisoquine hydroxylase locus and association with cancer susceptibility. Environ. Health Persp. 1992; 98: 107
   PubMedGoogle Scholar
• Smith T. J., Guo Z., Gonzalez F., Guengerich F. P., Stoner G. D., Yang C. S. Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P450 expressed in hepatoma cells. Cancer Res. 1992; 52: 1757
   PubMed Web of Science ®Google Scholar
• Crespi C. L., Penman B. W., Gelboin H. V., Gonzalez F. J. A tobacco smoke derived nitrosamine, 4-(methylnitrosamino)-1(3-pyridyl)-1-butanone, is activated by multiple human cytochrome P450s including the polymorphic cytochrome P4502D6. Carcinogenesis 1991; 12: 1197
   PubMed Web of Science ®Google Scholar
• Penman B. W., Reece J., Smith T., Yang C. S., Gelboin H. V., Gonzalez F. J., Crespi C. L. Characterization of a human cell line expressing high levels of cDNA-derived CYP2D6 locus. Nature 1990; 347: 773
   PubMedGoogle Scholar
• Widersten M., Pearson W. R., Engstrom A., Mannerik B. Heterologous expression of the allelic variant m-class glutathione transferases ö. and x. Biochem. J. 1991; 276: 519
   PubMed Web of Science ®Google Scholar
• Ayesh R., Idle J. R., Ritchie J. C., Crothers M. J., Hetzel M. R. Metabolic oxidation phenotypes as markers for susceptibility to lung cancer. Nature 1984; 32: 169
   Google Scholar
• Law M. R., Hetzel M. R., Idle J. R. Debrisoquine metabolism and genetic predisposition to lung cancer. Br. J. Cancer 1989; 59: 686
   PubMed Web of Science ®Google Scholar
• Harris C. C., Westor A., Willey J. C. (1988) Biochemical and molecular epidemiology of human cancer. Microsomes and Drug Oxidations. 1988, D. J. Birkett. Taylor & Francis, London, Proceedings of the 7th International Symposium
   Google Scholar
• Caporaso N. E., Tucker M. A., Hoover R. N., Hayes R. B., Pickle L. W., Issaq H. J., Muschik G. M., Green-Gallo L., Buivys D., Aisner S. Lung cancer and the debrisoquine metabolic phenotype. J. Natl. Cancer Inst. 1990; 82: 1264
   PubMed Web of Science ®Google Scholar
• Agundez J. A. G., Martinez C., Ladero J. M., Ledesma M. C., Ramos J. M., Martin R., Rodruguez A., Jara C., Benitez J. Debrisoquine oxidative genotype and susceptibility to lung cancer. Clin. Pharm. Ther. 1994; 55: 10
   PubMed Web of Science ®Google Scholar
• Bouchardy C., Benhamou S., Dayer P. The effect of tobacco on lung cancer risk depends on CYP2D6 activity. Cancer Res. 1996; 56: 251
   PubMed Web of Science ®Google Scholar
• Broly F., Meyer U. A. Debrisoquine oxidation polymorphism: phenotypic consequences of a 3 base pair deletion in exon 5 of the CYP206 gene. Pharmacogenetics 1993; 3: 123
   PubMedGoogle Scholar
• Rannug A., Alexandrie A-K., Persson I., Ingelman-Sundberg M. Genetic polymorphism of cytochromes P450 1A1, 2D6 and 2E1: regulation and toxicological significance. J. Occpat. Environ. Med. 1995; 37(1)25
   PubMedGoogle Scholar
• Drakoulis N., Minks T., Ploch M. Questionable association of debrisoquine hydroxlator phenotype and risk for bronchiol carcinoma. Acta. Pharmacol. Toxicol. 1986; 59: 220
   PubMedGoogle Scholar
• Benitez J., Ladero J. M., Jara C., Carrillo J. A., Cobaleda J., Llerena A., Vargas E., Munoz J. J. Polymorphic oxidation of debrisoquine in lung cancer patients. Eur. J. Cancer 1991; 27: 158
   PubMed Web of Science ®Google Scholar
• Duche J. C., Joanne C., Barre J., De Cremoux H., Dalphin J. C., Depierre A., Brochard P., Tillement J. P., Bechtel P. Lack of relationship between the polymorphism of debrisoquire oxidation and lung cancer. Br. J. Clin. Pharmacol. 1991; 31: 533
   PubMed Web of Science ®Google Scholar
• Stucker I., Cosme J., Laurent P. H., Cenee S., Beaune P. H., Bigman J., Depierre A., Milleron B., Hemon D. CYP2D6 genotype and lung cancer risk according to histologic type and tobacco exposure. Carcinogenesis 1995; 16(11)2759
   PubMedGoogle Scholar
• Shaw G. L., Falk R. T., Deslauriers J., Frame J. N., Nesbitt J. C., Pass H. I., Issaq H. J., Hoover R. N., Tucker M. A. Debrisoquine metabolism and lung cancer. Cancer Epid. Biom. Prev. 1995; 4: 41
   PubMed Web of Science ®Google Scholar
• Ingleman-Sundberg M., Johnson I., Perrson I. Genetic polymorphism of cytochromes P450. In-terethnic differences and relationsip to incidence of lung cancer. Pharmacogenetics 1992; 2: 264
   PubMedGoogle Scholar
• Bertilsson L., Lou Y. Q., Du Y. L., Liu Y., Kuang T. Y., Liao X. M., Wang K. Y., Reviriego J., Iselius L., Sjoqvist F. Pronounced differences between native Chinese and Swedish populations in the polymorphic hydroxylations of debrisoquine andS-mepheytoin. Clin. Pharmacol. Ther. 1992; 51: 388
   PubMed Web of Science ®Google Scholar
• Sugimura H., Caporaso N., Shaw G. L., Modali R. V., Gonzalez F. J., Hoover R. N., Resau J. H., Trump B. F., Weston A., Harris C. C. Human debrisoquine hydroxylase gene polymorphisms in cancer populations and controls. Carcinogenesis 1990; 11: 1527
   PubMed Web of Science ®Google Scholar
• Gough A. C., Miles J. S., Spurr M. K., Moss J. E., Gaedigk A., Eichelbaum M., Wolf C. R. Identification of the primary gene deficit at the cytochrome P450 CYP2D locus. Nature 1990; 347: 773
   PubMed Web of Science ®Google Scholar
• Heim M., Meyter U. A. Genotyping poor metabolizers of debrisoquine by allele-specific PCR amplification. Lancet 1990; 336: 529
   PubMed Web of Science ®Google Scholar
• Caporaso N. E., Shields P. G., Landi M. T., Shaw G. L., Tucker M. A., Hoover R., Sugimura H., Weston A., Harris C. C. The debrisoquine metabolic phenotype and DNA-based assays: implications of misclassification. Environ. Health Persp. 1992; 98: 101
   PubMed Web of Science ®Google Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Anttila S., Karjalainen A., Pelkonen O., Vainio H. PCR-based CYP2D6 genotyping for Finnish lung cancer patients. Pharmacogenetics 1993; 3: 19
   PubMedGoogle Scholar
• Tyndale T., Aoyama T., Broly F., Matsunaga T., Inaba T., Kalow W., Gelboin H. V., Meyer U. A., Gonzalez F. J. Identification of a new variant of CYP2D6 allele lacking the codon encody Lys-281: possible association with poor metabolize phenotype. Pharmacogenetics 1991; 1: 26
   PubMedGoogle Scholar
• Broly F., Gaedigk A., Heim M., Eichelbaum M., Morike K., Meyer U. A. Debrisoquine/spartane hydroxylation genotype and phenotype: analysis of common mutations and alleles of CYP2D6 in a European population. DNA Cell Biol. 1991; 8: 545
   Google Scholar
• Dahl M. L., Johansson I., Palmertz M. P., Ingelman-Sundberg M., Sjoqvist F. Analysis of the CYP2D6 gene in relation to debrisoquine and desipramine hydroxylation in a Swedish population. Clin. Pharmacol Ther. 1992; 51: 12
   PubMed Web of Science ®Google Scholar
• Uematsu F., Kikuchi H., Motomiya M., Abe T., Sagami I., Ohmachi T., Wakui A., Kanamaru R., Watanabe M. Association between RFLP of the human cytochrome P4502E1 gene and susceptibility to lung cancer. Jpn. J. Cancer Res. 1991; 82: 254
   PubMedGoogle Scholar
• Persson I., Johansson I., Bergling H., Dahl M-L., Seidegard J., Rylander R., Rannug A., Hogberg J., Sundberg M. I. Genetic polymorphism of cytochrome P4502E1 in a Swedish population: relationship to incidence of lung cancer. FEBS Lett. 1993; 319(3)207
   PubMedGoogle Scholar
• Hirvonen A., Husgafvel-Pursiainen K., Anttilo S., Karjalainen A., Vainio H. The humanCYP2E1 gene and lung cancer:DraI andRsaI restriction fragment length polymorphisms in a Finnish study population. Carcinogenesis 1993; 14(1): 85
   Google Scholar
• Kato S., Shields P. G., Caporaso N. E., Hoover R. N., Trump B. F., Sugimura H., Weston A., Harris C. C. Cytochrome P4502E1 genetic polymorphisms, racial variation and lung cancer risk. Cancer Res 1992; 52: 6712
   PubMed Web of Science ®Google Scholar
• Hamada G.S., Sugimura H., Suzuki I., Nagura K., Kiyokawa E., Iwase T., Tanaka M., Takahashi T., Watanabe S., Kino I. The heme-binding region polymorphism of cytochrome P4501A1 (CYP1A1), rather than theRsaI polymorphism of 2E1 (CYP2EI), is associated with lung cancer in Rio de Janeiro. Cancer Epid. Biom. Prev. 1995; 4: 63
   PubMedGoogle Scholar
• Hildesheim A., Chen C. J., Caporaso N. E., Cheng Y. J. Cytochrome P4502E1 genetic polymorphisms and risk of nasopharyngeal carcinoma: results from a case-control study conducted in Taiwan. Cancer Epid. Biom. Prev. 1995; 4: 607
   PubMed Web of Science ®Google Scholar
• Ketterer B., Harris J. M., Talaska G., Meyer D. J., Pemble S. E., Taylor J. B., Lang N. P., Kadlubar F. F. The human glutathioneS-transferase supergene family, its polymorphisms, and its effects on susceptibility to lung cancer. Environ. Health Persp. 1992; 98: 87
   PubMed Web of Science ®Google Scholar
• Daly A. K., Cholerton S., Armstrong M., Idle J. R. Genotyping for polymorphisms in xenobiotic metabolism as a prediction of disease susceptibility. Environ. Health Persp. 1994; 102: 55
   PubMed Web of Science ®Google Scholar
• Kensler T. W., Egner P. A, Davidson N. E., Roebuck B. D., Pikul A., Groopman J. D. Modulation of aflatoxin metabolism, aflatoxin N7-guanyl formation and hepatic tumorigenesis in rats fed ethoxyquine: role of induction of glutathioneS-transferases. Cancer Res. 1986; 46: 3924
   PubMed Web of Science ®Google Scholar
• Randerath E., Miller R. H., Mittal D., Avitts T. A., Dunsford H. A., Randerath K. Covalent DNA damage in tissues of cigarette smokers as determined by32P-postlabeling assay. J. Natl. Cancer Inst. 1989; 81: 341
   PubMed Web of Science ®Google Scholar
• Pinkus R., Weiner L. M., Daniel V. Role of quinone-mediated generation of hydroxyl radicals in the induction of glutathioneS-transferase gene expression. Biochemistry 1995; 34: 81
   PubMed Web of Science ®Google Scholar
• Jaiswal A. K. Antioxidant response element. Biochem. Pharmacol. 1994; 48: 439
   PubMed Web of Science ®Google Scholar
• Brockmoller J., Kerb R., Drakoulis N., Nitz M., Roots I. Genotype and phenotype of glutathioneS-transferase class ö isoenzymes ö and x in lung cancer patients and controls. Cancer Res. 1993; 53: 1004
   PubMed Web of Science ®Google Scholar
• Heckbert S. R., Weiss N. S., Hornung S. K., Eaton D. L., Motulsky A. G. GlutathioneS-transferase and expoxide hydrolase activity in human leukocytes in relation to risk of lung cancer and other smoking-related cancers. J. Natl. Cancer Inst. 1992; 84: 414
   PubMed Web of Science ®Google Scholar
• Soni M. G., Krishna T. P., Krishnaswamy K. Human leukocyte glutathioneS-transferase isozyme (class mu) and susceptibility to smoking-related cancers. J. Tox. Environ. Health 1995; 46: 1
   PubMed Web of Science ®Google Scholar
• Nijhoff W. A., Grubben J. A. L., Nagengast F. M., Jansen J. B., Verhagen H., Van Poppel G., Peters W. H. Effects of consumption of Brussels sprouts on intestinal and lymphocytic glutathioneS-transferases in humans. Carcinogenesis 1995; 16(9): 2125
   Google Scholar
• Offord E. A., Mace K., Ruffieux, Malnoe A., Pfeifer A. M. A. Rosemary components inhibit benzo[a]pyrene-induced genotoxicity in human bronchial cells. Carcinogenesis 1995; 16(9): 2057
   Google Scholar
• Seidegard J., Varachek W. R., Pero R. W., Pearson W. R. Hereditary differences in the expression of the human glutathioneS-transferase active on trans-stilbene oxide are due to a gene deletion. PNAS 1988; 85: 7293
   PubMed Web of Science ®Google Scholar
• Fryer A. A., Zhao L., Alldersea J., Boggild M. D., Perrett C. W., Clayton R. N., Jones P. W., Strange R. C. The glutathioneS-transferases: polymerase chain reaction studies on the frequency of the GSTM1*0 genotype in patients with pituitary adenomas. Carcinogenesis 1993; 14: 563
   PubMed Web of Science ®Google Scholar
• Bell D. A., Thompson C. L., Taylor J., Miller C. R., Perera F., Hsieh L. L., Lucier G. W. Genetic monitoring of human polymorphic cancer susceptibility genes by polymerase chain reaction: application to glutathione transferase ö. Environ. Health Persp. 1992; 98: 113
   PubMed Web of Science ®Google Scholar
• Shields P. G., Baumen E. D., Harrington A. M. Polycycle aromatic hydrocarbon DNA adducts in human lung and cancer susceptibility genes. Cancer Res. 1993; 53: 3486
   PubMed Web of Science ®Google Scholar
• Ryberg D., Hewer A., Phillips D. H., Haugen A. Different susceptibility to smoking-induced DNA damage among male and female lung cancer patients. Cancer Res. 1994; 54: 5801
   PubMed Web of Science ®Google Scholar
• Kato S., Bowman E., Harrington A., Blomeke B., Shields P. G. Human lung carcinogen-DNA adductlevels mediated by genetic polymorphisms in vivo. JNCI 1902; 87(12)
   Google Scholar
• Cheng T. J., Christiani D. C., Xu X., Wain J. C., Wiencke J. K., Kelsey K. T. GlutathioneS-transferase ö genotype, diet and smoking as determinants of sister chromatid exchange frequency in lymphocytes. Cancer Epid. Biom. Prev. 1995; 4: 535
   PubMed Web of Science ®Google Scholar
• Wiencke J. K., Pemble S., Ketterer B., Kelsey K. T. Gene deletion of glutathioneS- transferase: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epid. Biom. Prev. 1995; 4: 253
   PubMed Web of Science ®Google Scholar
• Ryberg D., Kure E., Lystad S., Skaug V., Stangeland L., Mercy I., Borresen A. L., Haugen A. p53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res. 1994; 54: 1551
   PubMed Web of Science ®Google Scholar
• Seidegard, Peru J.R. W., Markowitz M. M., Roush G., Miller D. G., Beattie E. J. Isozymes of glutathione transferase (class mu) as a marker for the susceptibility to lung cancer: a follow-up study. Carcinogenesis 1990; 11: 33
   PubMed Web of Science ®Google Scholar
• Zhong S., Howie A. F., Ketterer B., Taylor J., Hayes J. D., Beckett G. J., Wathen C. G., Wolf C. R., Spurr N. K. GlutathioneS-transferase mu locus: use of genotyping and phenotyping assays to assess association with lung cancer susceptibility. Carcinogenesis 1991; 12: 1533
   PubMed Web of Science ®Google Scholar
• Kihara M., Noda K., Kihara M. Distribution ofGSTM1 null genotype in relation to gender, age, and smoking status in Japanese lung cancer patients. Pharmacogenetics 1995; 5: S74
   Google Scholar
• Hirvonen A., Husgafvel-Puriainen K., Anttila S., Vainio H. TheGSTM1 null genotype as a potential risk modifier for squamous cell carcinoma of the lung. Carcinogenesis 1993; 14: 1479
   PubMed Web of Science ®Google Scholar
• Nazar-Stewart V., Motulsky A. G., Eaton D. L., White E., Hornung S. K., Leng Z. T., Stapleton P., Weiss N. S. The glutathioneS-transferase ö polymorphism as a marker for susceptibility to lung carcinoma. Cancer Res. 1993; 53: 2313
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Watanabe J., Eguchi H., Hayashi S. Genetic polymorphisms of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics 1995; 5: S70
   PubMedGoogle Scholar
• Nakachi K., Imai K., Hayashi S., Kawejiri K. Polymorphisms of the CYP1Al and GST genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993; 53: 2994
   PubMed Web of Science ®Google Scholar
• Alexandrie A. K., Sundberg M. I., Seidegard J., Tornling G., Rannug A. Genetic susceptibility to lung cancer with special emphasis on CYP1A1 and GSTM1. Carcinogenesis 1995; 15(9)1785
   Google Scholar
• McWilliams J. E., Sanderson B. J. S., Harris E. L., Richert-Boe K. E., Henner W. D. GlutathioneS-transferase M1 deficiency and lung cancer risk. Cancer Epid. Biom. Prev. 1995; 4: 589
   PubMed Web of Science ®Google Scholar
• Lafuente A., Pujol F., Carretero P., Villa J. P., Cuchi A. Human glutathioneS-transferase ö gene deficiency as a marker for the susceptibility to bladder and larynx cancer among smokers. Cancer Lett. 1993; 68: 49
   PubMed Web of Science ®Google Scholar
• Bell D. A., Taylor J. A., Paulson D. F., Robertson C. N., Mohler J. L., Lucier G. W. Genetic risk and carcinogen exposure: a common inherited defect of carcinogen-metabolism gene glutathioneS-transferase M1 that increases susceptibility to bladder carcinoma. JNCI 1993; 85: 1159
   PubMed Web of Science ®Google Scholar
• Zhong S., Wyllie A. H., Barnes D., Wolf C. R., Spurr N. K. Relationship between theGSTM1 genetic polymorphism and susceptibility to bladder, breast and colon cancer. Carcinogenesis 1993; 14: 1821
   PubMed Web of Science ®Google Scholar
• Powis G. Free radical formation by antitumor quinoes. Free Rod. Biol. Med. 1989; 6: 63
   PubMed Web of Science ®Google Scholar
• Fisher G. R., Patterson L. H., Gutierrez P. L. A comparison of free radical formation by quinone antitumor agents in MCF-7 cells and the role of NAD(P)H:(Quinone-Acceptor) oxidoreductase (DT-Diaphorase). Chem. Biol. Interaction 1993; 137
   Google Scholar
• Nutler L. M., Ngo E. O., Fisher G., Gutierrez P. L. DNA-strand scission and free radical production in menadane-treated cells. J. Biol. Chem. 1992; 267: 2474
   PubMedGoogle Scholar
• Chesis P. L., Levin D. E., Smith M. T., Ernster L., Ames B. N. Mutagenicity of quinones: pathways of metabolic activation and detoxification. PNAS 1984; 81: 1696
   PubMed Web of Science ®Google Scholar
• Schlager J. J., Powis G. Cytoslic NAD(P)H: (Quinone-Acceptor) oxidoreductase in human normal and tumor tissue. Effects of cigarette smoking and alcohol. Int. J. Cancer 1990; 45: 403
   PubMed Web of Science ®Google Scholar
• Offord E. A., Mace K., Ruffieux, Malnoe A., Pfeifer A. M. A. Rosemary components inhibit benzo[a]pyrene-induced genotoxicity in human bronchial cells. Carcinogenesis 1995; 16(9): 2057
   Google Scholar
• Edwards T. H., Potter J., Hopkins D. A. Human FAD-dependent NAD(P)H diaphorase. Bio-chem. J. 1985; 187: 429
   Google Scholar
• Belinsky M., Jaiswal A. K. NAD(P)H: Quinone oxidoreductase, (DT-diaphorase) expression in normal and tumor tissues. Cancer Metastasis Rev. 1993; 12: 103
   PubMed Web of Science ®Google Scholar
• Rushmore T. H., Morton M., Pickett C. B. The antioxide responsive element. J. Biol. Chem. 1991; 266: 11632
   PubMed Web of Science ®Google Scholar
• Jaiswal A., Burnett P., Adesnik M., McBride O. W. Nucleotide and deduced amino acid sequence of a human cDNA (NQO2) corresponding to a second member of the NAD(P)H: Quinone oxidoreductase gene family. Extensive polymorphisms of the NQO2 gene locus in chromosome 6. Biochemistry 1990; 29: 1899
   PubMed Web of Science ®Google Scholar
• Siegel D., Traver R. D., Beall H. D. Cloning and purification of a mutant DT-diaphorase protein from human colon and lung cancer cell lines. Proc. Am. Assoc. Cancer Res. 1995; 36: 1729
   Google Scholar
• Nakachi K., Imai K., Hayashi S., Kawejiri K. Polymorphisms of the CYP1A1 and GST genes associated with susceptibility to lung cancer in relation to cigarette dose in a Japanese population. Cancer Res. 1993; 53: 2994
   PubMed Web of Science ®Google Scholar
• Kihara M., Kihara M., Noda K. Risk of smoking for squamous and small cell carcinomas of the lung modulated by combinations ofCYP1A1 andGSTM1 gene polymorphisms in a Japanese population. Carcinogenesis 1995; 16(10): 2331
   Google Scholar
• Kato S., Bowman E., Harrington A., Blomeke B., Shields P. G. Human lung carcinogen-DNA adduct levels mediated by genetic polymorphisms in vivo. J. Natl. Cancer Inst. 1902; 87(12)
   Google Scholar
• Marnett L. J., Burcham P. C. Alkylation damage, DNA repair, and mutagenesis in human cells. Chem. Res. Toxicol. 1993; 6: 771
   PubMed Web of Science ®Google Scholar
• Phillips D. H., Schoket B., Hewer A., Bailey E., Kostic S., Vincze I. Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int. J. Cancer 1990; 46: 569
   PubMed Web of Science ®Google Scholar
• Cuzick J., Routledge M. N, Jenkins D., Garner R. C. DNA adducts in different tissues of smokers and non-smokers. Int. J. Cancer 1990; 45: 673
   PubMed Web of Science ®Google Scholar
• Dunn B. P., Vedal S., San R. H. C., Kwan W. F., Nelems B., Enarson B., Stich H. F. DNA adducts in bronchial biopsies. Int. J. Cancer 1991; 48: 485
   PubMedGoogle Scholar
• Bartsch H., Castegnaro M., Camus A. M., Schouft A., Geneste O., Rojas M., Alexandrov K. Analysis of DNA adducts in smokers' lung and urothelium by32P-postlabeling: metabolic phenotype dependence and comparison with other exposure markers. Postlabeling Methods for Detection of DNA Products, D. H. Phillips, M. Castegnaro, H. Bartsch. IARC, Lyons 1993; 331
   Google Scholar
• Philips D. H., Hewer A., Martin C. M., Garner R. C., King M. M. Correlation of DNA adduct levels in human lung with cigarette smoking. Nature 1988; 336: 790
   PubMedGoogle Scholar
• VanSchooten F. J., Hillebrand M. J. X., Van Leeuwen F. E., Lutgerink J. T., Van Zandwijk N., Jansen H. M., Kriek E. PAH-DNA of adducts in lung tissue from lung cancer patients. Carcinogenesis 1990; 11: 1677
   PubMedGoogle Scholar
• Perera F., Mayer J., Jaretzki A., Hearne S., Brenner D., Young T. L., Fischman H. K., Grimes M., Grantham S., Tang M. X. Comparison of DNA adducts and sister chromatid exchange in lung cancer cases and controls. Cancer Res. 1989; 49: 4446
   PubMed Web of Science ®Google Scholar
• Weston A., Bowman E. D., Shields P. G., Trivers G. E., Poirier M. C., Santella R. M., Manchester D. K. Detection of polycyclic aromatic hydrocarbon-DNA adducts in human lung. Environ. Health Persp. 1993; 99: 257
   PubMedGoogle Scholar
• Tang D., Santella R. M., Blackwood A. M., Young T. L., Mayer J., Jaretzki A., Grantham S., Tsai W. Y., Perera F. P. A molecular epidemiological case-control study of lung cancer. Cancer Epid. Biom. Prev. 1995; 4: 341
   PubMed Web of Science ®Google Scholar
• Shields P. G., Bowman E. D., Harrington A. M. Polycycle aromatic hydrocarbon DNA adducts in human lung and cancer susceptiblity genes. Cancer Res. 1993; 53: 3486
   PubMed Web of Science ®Google Scholar
• Stern S. J., Degawa M., Martin M. V., Guengerich F. P., Kaderlik R. K., Ilett K. F., Breau R., McGhee M., Montague D., Lyn-Cook B. Metabolic activation, DNA adducts and h-ras mutations in human neoplastic and non-neoplastic laryngeal tissue. J. Cell Biochem. Suppl. 1993; 17F: 129
   PubMedGoogle Scholar
• VanSchooten F. J., Hillebrand M. J. X., Van Leeuwen F. E., Van Zandwijk N., Jansen H. M., Den Engelse L., Kriek E. PAH-DNA adducts in white blood cells from lung cancer patients: no correlation with adduct levels. Carcinogenesis 1992; 13: 987
   PubMedGoogle Scholar
• Schell C., Popp W., Kraus R., Vahrenholz C., Norpoth K. 32P-Postlabeling analysis of DNA adducts in different populations. Toxicol. Lett. 1995; 77: 299
   PubMedGoogle Scholar
• Savela K., Hemminki K. DNA adducts in lymphocytes and granulocytes of smokers and nonsmokers detected by the32P-postlabeling assay. Carcinogenesis 1991; 12(3)503
   PubMedGoogle Scholar
• Savela K., Hemminki K. Analysis of cigarette smoke-induced DNA adducts by butanol extraction and nuclease P1-enhanced32P-postlabeling in human lymphocytes and granulocytes. Env. Health Persp. 1993; 101: 145, (Suppl. 3)
   PubMedGoogle Scholar
• Mooney L. A., Santella R. M., Covey L., Jeffrey A. M., Bigbee W., Randall M. C., Cooper T. B., Ottman R., Tsai W. Y., Wazneh L. Decline of DNA damage and other biomarkers in peripheral blood following smoking cessation. Cancer Epid. Biom. Prev. 1995; 4: 627
   PubMed Web of Science ®Google Scholar
• Santella R. M., Grinberg-Funes R. A., Young T. L., Dickey C., Singh V. N., Wang L. W., Perera F. P. Cigarette smoking-related polycyclic aromatic hydrocarbon-DNA adducts in peripheral mononuclear cells. Carcinogenesis 1992; 13: 2041
   PubMed Web of Science ®Google Scholar
• Van Schooten F. J., Jongeneelen F. J., Hillebrand M. J. X., Van Leeuwen F. E., De Looff A. J., Dijkmans A. P., Van Rooij J. G., Den Engelse L., Kriek E. Polycyclic aromatic hydrocarbon-DNA adducts in white blood cell DNA and 1-hydroxypyrene in the urine from aluminum workers: relation with job category with synergistic effect of smoking. Cancer Epid. Biom. Prev. 1995; 4: 69
   PubMed Web of Science ®Google Scholar
• Perera F. P., Santella R. M., Brenner D. DNA adducts, protein adducts and sister chromatid exchange in cigarette smokers and non-smokers. JNC1. 1987; 79: 449
   PubMed Web of Science ®Google Scholar
• Philips D. H., Schoket B., Hewer A., Bailey E., Kostic S., Vincze I. Influence of cigarette smoking on the levels of DNA adducts in human bronchial epithelium and white blood cells. Int. J. Cancer 1990; 46: 569
   PubMedGoogle Scholar
• Van Maaner J. M. S., Maas L. J., Hagema G., Kleinjans J. C., Van Agen B. DNA adduct and mutation analysis in WBCs of smokers and nonsmokers. Environ. Mol. Mut. 1994; 24: 46
   PubMedGoogle Scholar
• Van Maanen J. M. S., Moonen E. J. C., Maas L. M., Kleinjans J. C. S., Van Schooten F. J. Formation of aromatic DNA adducts in white blood cells in relation to urinary excretion of 1-hydroxypyrene during consumption of grilled meat. Carcinogenesis, 15(10)2263
   PubMedGoogle Scholar
• Rothman N., Poirer M. C., Haas R. A., Correa-Villasenor A., Ford P., Hansen J. A., O'Toole T., Stickland P. T. Association of PAH-DNA adducts in peripheral WBCs with dietary exposure to PAHs. Environ. Health Persp. 1993; 99: 265
   PubMedGoogle Scholar
• Rothman N., Correa-Villasenor A., Ford D. P., Poirier M. C., Haas R., Hansen J. A., O'Toole T., Strickland P. T. Contribution of occupation and diet to white blood cell polycyclic aromatic hydrocarbon-DNA adducts in wildland firefighters. Cancer Epid. Biom. Prev. 1993; 2: 341
   PubMed Web of Science ®Google Scholar
• Kriek E., Van Schoeten F. J., Hillebrand M. J. X., Van Leeuwen F. E., Den Engelse L., De Loof A. J., Dijkmans A. P. DNA adducts as a measure of lung cancer risk in humans exposed to PAH. Environ. Health Persp. 1993; 99: 71
   PubMed Web of Science ®Google Scholar
• Hemminki K., Gryzbowska E., Chorazy M., Twardowska-Saucha K., Sroczynski J. W., Putman K. L., Randerath K., Phillips D. H., Hewer A., Santella R. M. DNA adducts in humans environmentally exposed to aromatic compounds in an industrial area of Poland. Carcinogenesis 1990; 11(7)1229
   PubMed Web of Science ®Google Scholar
• Hemminki K., Gryzbowska E., Chorazy M., Twardowska-Saucha K., Sroczynski J. W., Putman K. L., Randerath K., Phillips D. H., Hewer A., Santella R. M. DNA adducts in humans environmentally exposed to aromatic compounds in an industrial area of Poland. Carcinogenesis 1990; 11(7)1229
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Eguchi H., Nakachi K., Sekiya T., Yamamoto M. Association ofCYP1A1 germ line polymorphisms with mutations of the p53 gene in lung cancer. Cancer Res. 1996; 56: 72
   PubMed Web of Science ®Google Scholar
• Grinberg-Funes R. A., Singh V. N., Perera F. P., Bell D. A., Young T. L., Dickey C., Wang L. W., Santella R. M. Polycyclic aromatic hydrocarbon-DNA adducts in smokers and their relationship to micronutrient levels and the glutathioneS-transferase Ml genotype. Carcinogenesis 1994; 15(11): 2449
   Google Scholar
• Kriek E., Van Schoeten F. J., Hillebrand M. J. X., Van Leeuwen F. E., Den Engelse L., De Looff A. J., Dijkmans A. P. DNA adducts as a measure of lung cancer risk in humans exposed to PAH. Environ. Health Persp. 1993; 99: 71
   PubMed Web of Science ®Google Scholar
• Hoffman D., Brunneman K. D., Poropczyk B., Djordevic M. V. Tobacco-specificN-nitrosamines andareca-derivedN-nitrosamines: chemistry, biochemistry, carcinogenicity, and relevance to humans. J. Tox. Env. Health 1994; 41: 1
   PubMedGoogle Scholar
• Hecht S. S., Carmella S. G., Foiles P. G., Murphy S. E. Biomarkers for human uptake and metabolic activation of tobacco-specific nitrosamines. Cancer Res. 1994; 54: 1912
   PubMed Web of Science ®Google Scholar
• Foiles P. G., Akerkar S. A., Carmella S. G., Kagan M. Mass spectrometric analysis of tobacco-specific nitroamine-DNA adducts in smokers and nonsmokers. Chem. Res. Toxicol. 1991; 4: 364
   PubMed Web of Science ®Google Scholar
• Foiles P. G., Murphy S. E., Peterson L. A., Carmella S. G., Hecht S. S. DNA and hemoglobin adducts as markers of metabolic activation of tobacco-specific carcinogens. Cancer Res. 1992; 52(Suppl.)2698s
   Google Scholar
• Mustonen R., Hemminki K. 7-Methylguanine levels in DNA of smokers' and non-smokers' total white blood cells, granulocytes and lymphocytes. Carcinogenesis 1992; 13(11)1951
   PubMedGoogle Scholar
• Flehinger B. L., Kimmel M., Polyck T., Melamed M. R. Screening for lung cancer: the Mayo lung project revisited. Cancer 1993; 72: 1573
   PubMed Web of Science ®Google Scholar
• Wilson V. L., Weston A., Manchester D. K., Trivers G. E., Roberts D. W., Kadlubar F. F., Wild C. P., Montesano R., Willey J. C., Mann D. L. Alkyl and aryl carcinogen adducts detected in human peripheral lung. Carcinogenesis 1989; 10: 2149
   PubMed Web of Science ®Google Scholar
• Lin D., Lay J. O., Bryant M. S. Analysis of 4-aminobiphenyl-DNA adducts in human urinary bladder and lung
   Google Scholar
• Weston A., Caporaso N. E., Taghizadeh K. Measurements of 4ABP-hemoglobin adducts in lung cancer cases and controls. Cancer Res. 1991; 51: 5219
   PubMedGoogle Scholar
• Cheng T. J., Christiani D. C., Xu X., Wain J. C., Wiencke J. K., Kelsey K. T. GlutathioneS-transferase ö genotype, diet and smoking as determinants of sister chromatid exchange frequency in lymphocytes. Cancer Epid. Biom. Prev. 1995; 4: 535
   PubMed Web of Science ®Google Scholar
• Bender M. A., Preston R. J., Leonard R. C., Pyatt B. E., Gooch P. C., Shelby M. D. Chromosomal aberration and sister chromatid exchange frequencies in peripheral blood lymphocytes of a large human population sample. Mutat. Res. 1988; 204: 421
   PubMed Web of Science ®Google Scholar
• Nordic Study Group. A Nordic data base on somatic chromosome damage in humans. Mutat. Res. 1990; 241: 325
   PubMedGoogle Scholar
• Wiencke J. K., Pemble S., Ketterer B., Kelsey K. T. Gene deletion of glutathioneS-transferase: correlation with induced genetic damage and potential role in endogenous mutagenesis. Cancer Epid. Biom. Prev. 1995; 4: 253
   PubMed Web of Science ®Google Scholar
• Spitz M. R., Hsu T. C. Mutagen sensitivity as a marker of cancer risk. Cancer Detect. Prev. 1994; 18(4)299
   PubMedGoogle Scholar
• Cariello N. F., Skopek T. R. In vivo mutation at the human HPRT locus. TIG 1993; 9: 322
   PubMedGoogle Scholar
• Albertini R. J., Nicklas J. A., Fuscoe J. C., Skopek T. R., Branda R. F., O'Neill J. P. In vivo mutations in human blood cells: biomarkers for molecular biology. Environ. Health Persp. 1993; 99: 135
   PubMedGoogle Scholar
• Cole J., Green M. J. L., James S. E., Henderson L., Cole H. A further assessment of factors influencing measurements of throguanine-resistant mutant frequency in circulating T-lymphoyctes. Mutat. Res. 1988; 204: 493
   PubMedGoogle Scholar
• Perera F. P., Dickey C., Santella R., O'Neill J. P., Albertini R. J., Ottman R., Tsai W. Y., Mooney L. A., Savela K., Hemminki K. Carcinogen-DNA adducts and gene mutation in founding workers with low-level exposure to polycyclic aromatic hydrocarbons. Carcinogenesis 1994; 15: 2905
   PubMedGoogle Scholar
• Citron M., Decker R., Chen S., Schneider S., Graver M., Kleynerman L., Kahn L. B., White A., Schoenhaus M., Yarosh D. O6-methylguanine-DNA methyltransferase in human normal and tumour tissue from brain, lung, and ovary. Cancer Res. 1991; 51: 4131
   PubMed Web of Science ®Google Scholar
• Oberli-Schrammli A. E., Joncourt F., Stadler M., Altermatt H-J., Buser K., Ris H. B., Schmid U., Cerny T. Parallel assessment of glutathione-based detoxifying enzymes, O6-alkylguanine-DNA alkyltransferase and P-glycoprotein as indicators of drug in tumor and normal lung of patients with lung cancer. Int. J. Cancer 1994; 59: 629
   PubMed Web of Science ®Google Scholar
• Drin I., Schoket B., Kostic S., Vincze I. Smoking-related increase in O6-alkylguanine-DNA alkyltransferase activity in human lung tissue. Carcinogenesis 1994; 15(8)1535
   PubMedGoogle Scholar
• Rodenhuis S., Slebos R. J. C. Clinical significance ofras oncogene activation in human lung cancer. Cancer Res. 1992; 52: 2665s, (Suppl.)
   PubMed Web of Science ®Google Scholar
• Reynolds S. H., Anderson M. W. Activation of protooncogenes in human and mouse lung tumors. Environ. Health Persp. 1991; 93: 145
   PubMed Web of Science ®Google Scholar
• Anderson M. W., Reynolds S. H., You M., Maronpot R. M. Role of protooncogene activation in carcinogenesis. Environ. Health Persp. 1992; 98: 13
   PubMed Web of Science ®Google Scholar
• Mills N. E., Fishman C. L., Rom W. N., Dubin N., Jacobson D. Increased prevalence ofk-ras oncogene mutations in lung adenocarcinoma. Cancer Res. 1995; 55: 1444
   PubMed Web of Science ®Google Scholar
• Sugimura H., Caporaso N. E., Modali R. V., Hoover R. N. Association of rare alleles of the Harveyras protooncogene locus with lung cancer. Cancer Res. 1990; 50: 1857
   PubMed Web of Science ®Google Scholar
• Husgafvel-Pursiainen, Ridanpaa M., Anttila S., Vainio H. p53 andras gene mutations in lung cancer: implications for smoking and occupational exposures. J. Occ. Env. Med. 1995; 37(1)69
   PubMedGoogle Scholar
• Yakubovskaya M. S., Spiegelman V., Luo F. C., Malaev S. High frequency of k-ras mutations in normal appearing lung tissues and sputum of patients with lung cancer. Int. J. Cancer 1995; 63: 810
   PubMedGoogle Scholar
• Mao L., Hruban R. H., Boyle J. O., Tockman M., Sidransky D. Detection of oncogene mutations in sputum precedes diagnosis of lung cancer. Cancer Res. 1994; 54: 1634
   PubMed Web of Science ®Google Scholar
• Brandt-Rauf P. W., Smith S. J., Perera F. P. Molecular epidemiology and environmental carcinogenesis of the lung. Probl. Resp. Car. 1990; 3: 44
   Google Scholar
• Weissfield J. L., Larsen R. D., Niman H. L., Kuller L. H. Evaluation of oncogene-related proteins in serum. Cancer Epid. Biom. Prev. 1994; 3: 57
   PubMedGoogle Scholar
• Sugio K., Kishimoto Y., Virmani A. K., Hung J., Gazdar A. F. K-ras mutations are a relatively late event in the pathogenesis of lung carcinomas. Cancer Res. 1994; 54(22): 5811
   Google Scholar
• Li Z-H., Zheng J., Weiss L. M., Shibata D. c-K-ras andp53 mutations occur very early in adenocarcinoma of the lung. Am. J. Pathol. 1994; 144(2): 303
   Google Scholar
• Rodenhuis S., Slebos R. J. C. Clinical significance ofras oncogene activation in human lung cancer. Cancer Res. 1992; 52: 2665s
   PubMed Web of Science ®Google Scholar
• Ryberg D., Tefre T., Skaug V., Stangeland L., Ovrebo S., Naalsund A., Borresen A. L., Haugen A. Allele diversity of the h-ras-l variable number of tandem repeats in Norwegian lung cancer patients. Environ. Health Persp. 1992; 98: 187
   PubMedGoogle Scholar
• Krontiris T. G., Devlin B., Karp D. D., Robert N. J., Risch N. An association between the risk of cancer and mutations in theh-ras-1 minisatellite locus. NEJM 1993; 329(8): 518
   Google Scholar
• Brandt-Rauf P. W., Luo J. C., Carney W. P., Smith S., DeVivo I., Milling C., Hemminki K., Koskinen H., Vainio H., Neugut A. I. Detection of increased amounts of the extracellular domain of the cerbB-2 oncoprotein in serum during pulmonary carcinogenesis in humans. Int. J. Cancer 1994; 56: 383
   PubMedGoogle Scholar
• Shi D., He G., Cao S., Pan W., Zhang H. Z., Yu D., Hung M. C. Overexpression of the c-erbB-2/neu-encoded p185 protein in primary lung cancer. Mol. Carcinogen. 1992; 5: 213
   PubMed Web of Science ®Google Scholar
• Paako P., Nuorva K., Kamel D., Soini Y. Evidence byin situ hybridization that c-erbB- 2 protooncogene expression is a marker of malignancy and is expressed in lung adenocarcinomas. Am. J. Resp. Cell. Mol. Biol. 1992; 7: 325
   PubMedGoogle Scholar
• King C. R., Krauss M. H., DiFiore P. P., Paik S., Kaspryzk P. G. Implications oferbB-2 over-expression for basic science and clinical medicine. Semin. Cancer Biol. 1990; 1: 329
   PubMedGoogle Scholar
• Gazzeri S., Brambilla E., De Fromentel C., Gouyer V., Moro D., Perron P., Berger F., Brambilla C. p53 genetic abnormalities andmyc activation in human lung carcinoma. Int. J. Cancer 1994; 58: 24
   PubMedGoogle Scholar
• Pfeifer A. M. A., Jones R. T., Bowden P. E., Mann D., Spillare E., Klein-Szanto A. J., Trump B. F., Harris C. C. Human bronchial epithelial cells transformed by the c-raf-1 and c-myc protooncogenes induce multidifferentiated carcinomas in nude mice: a model for lung carcinogenesis. Cancer Res. 1991; 51: 3793
   PubMed Web of Science ®Google Scholar
• Broers J. L., Viallet J., Jensen S. M., Pass H., Travis W. D., Minna J. D., Linnoila R. I. Expression of c-myc in progenitor cells of the bronchopulmonary epithelium and in a large number of non-small cell lung cancers. Am. J. Resp. Cell Mol. Biol. 1993; 9: 33
   PubMed Web of Science ®Google Scholar
• Weston A., Ling-Cawley H., Caparoso N. E., Bowman E. D., Hoover R. N., Trump B. F., Harris C. C. Determination of the allelic frequencies of an L-myc and ap53 polymorphism in human lung cancer. Carcinogenesis 1994; 15(4): 583
   Google Scholar
• Schauer I. E., Siriwardana S., Langan T. A., Sclafani R. A. Cyclin D1 overexpression vs. retinoblastoma inactivation: implications for growth control evasion in non-small cell and small cell lung cancer. Proc. Natl. Acad. Sci. U.S.A. 1994; 91: 7827
   PubMed Web of Science ®Google Scholar
• Morgan D. O. Principles of CDK regulation. Nature 1995; 314: 131
   Google Scholar
• Hollingsworth R. E., Jr., Chen P. L., Lee W. H. Integration of cell cycle control with transcriptional regulation by the retinoblastoma protein. Curr. Opin. Cell. Biol 1993; 5(2)194
   PubMedGoogle Scholar
• Buckley M. F., Sweeney K. J. E., Hamilton J. A., Sini R. L., Manning D. L., Nicholson R. I., DeFazio A., Watts C. K., Musgrove E. A., Sutherland R. L. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993; 8(8)2127
   PubMed Web of Science ®Google Scholar
• Jiang W., Zhang Y-J., Kahn S. M., Hollstein M. C., Santella R. M., Lu S. H., Harris C. C., Montesano R., Weinstein I. B. Altered expression of the cyclin D1 and retinoblastoma genes in human esophageal cancer. Proc. Natl. Acad. Sci. U.S.A. 1993; 90: 9026
   PubMed Web of Science ®Google Scholar
• Zhang Y-J., Jiang W., Chen C. J., Lee C. S., Kahn S. M., Santella R. M., Weinstein I. B. Amplification and overexpression of cyclin D1 in human hepatocellular carcinoma. Biochem. Biophys. Res. Comm. 1993; 196: 1010
   PubMed Web of Science ®Google Scholar
• Betticher D. C., Thatcher N., Altermatt H. J., Hoban P., Ryder W. D., Heighway J. Alternate splicing produces a novel cyclin D1 transcript. Oncogene 1995; 11: 1005
   PubMed Web of Science ®Google Scholar
• Keyomarsi K., Conte D., Toyofuku W., Fox M. P. Deregulation of cyclin E in breast cancer. Oncogene 1995; 11: 941
   PubMed Web of Science ®Google Scholar
• Harris C. C., Hollstein M. Clinical implications of the p53 tumor-suppressor gene. N. Engl. J. Med. 1993; 329(18)1318
   PubMed Web of Science ®Google Scholar
• Birrer M. J., Brown P. H. Application of molecular genetics to the early diagnosis and screening of lung cancer. Cancer Res. 1992; S52: 2658s
   Google Scholar
• Levin W. L., Casey G., Ramos J., Arboleda M. J., Reissman P. T., Slamon D. J. Tumor suppressor and immediate early transcription factor genes in NSC lung cancer. Chest 1994; 106(6S)372
   Google Scholar
• Livingstone L. R., White A., Sprouse J., Livanos E., Jacks T., Tlsty T. D. Altered cell cycle arrest and gene amplification potential accompany loss of wild-type p53. Cell 1992; 70: 937
   PubMedGoogle Scholar
• Kastan M. B., Onyekewere O., Sidransky D., Vogelstein B., Craig R. W. Participation of p53 protein in the cellular response to DNA damage. Cancer Res. 1991; 51: 6304
   PubMed Web of Science ®Google Scholar
• Caelles C., Helmberg A., Karin M. p53-dependent apoptosis in the absence of transcriptional activation of p-53 target genes. Nature 1994; 370(370)220
   PubMedGoogle Scholar
• Levine A. J., Perry M. E., Chang A., Silver A., Dittmer D., Wu M., Welsh D. The 1993 Walter Hubert Lecture: the role of the p53 tumor-suppressor gene in tumorigenesis. Br. J. Cancer 1994; 69: 409
   PubMed Web of Science ®Google Scholar
• Srivastava S., Zou Z. Q., Piollo K., Blattner W., Chang E. H. Germ-line transmission of a mutated p53 gene in a cancer prone family with Li-Fraumeni syndrome. Nature 1990; 348: 747
   PubMed Web of Science ®Google Scholar
• Iggo R., Gatter K., Bartek J., Lane D., Harris A. L. Increased expression of mutant forms of p53 oncogene in primary lung cancer. Lancet 1990; 335: 675
   PubMed Web of Science ®Google Scholar
• Bennett W. P. p53 alterations in progenitor lesions of the bronchus, esophagus, oral cavity and colon. Cancer Detect. Prev. 1995; 19: 503
   PubMedGoogle Scholar
• Melhem M. F., Law J. C., El Ashmawy L., Johnson J. T., Landreneau R. J., Srivastava S., Whiteside T. L. Assessment of sensitivity and specificity of immunohistochemical staining of p53 in lung and head and neck cancers. Am. J. Pathol 1995; 146(5)1170
   PubMedGoogle Scholar
• Fujino M., Dosaka-Akita H., Kato M., Kinoshita I., Akie K., Kawakami Y. Simultaneous use of the PC-SSCP method and immunohistochemistry for increasing the detection efficacy of p53 abnormalities in human lung cancer. Am. J. Clin. Pathol. 1995; 104(3)319
   PubMedGoogle Scholar
• Top B., Mooi W. J., Klaver S. G., Boerrigter L., Wisman P., Elbers H. R., Visser S., Rodenhuis S. Comparative analysis ofp53 gene mutations and protein accumulation in human nonsmall cell cancer. Int. J. Cancer (Pred. Oncol.) 1995; 64: 83
   PubMed Web of Science ®Google Scholar
• Lane D. P. p53, guardian of the genome. Nature 1992; 358: 15
   PubMed Web of Science ®Google Scholar
• Hirano T., Franzen B., Kato H., Ebihara Y., Auer G. Genesis of Squamous cell lung carcinoma: sequential changes of proliferation, DNA ploidy and p53 expression. Am. J. Pathol. 1994; 144(2)
   Google Scholar
• Westra W. H., Offerhaus G. J., Goodman S. N., Slebos R. J., Polak M., Baas I. O., Rodenhuis S., Hruban R. H. Overexpression of thep53 tumor suppressor gene product in primary lung adenocarcinomas is associated with cigarette smoking. Am. J. Surg. Pathol. 1993; 17: 213
   PubMed Web of Science ®Google Scholar
• Taylor J. A., Watson M. A., Devereux T. R., Michels R. Y., Saccomanno G., Anderson M. p53 mutation hotspot in radon-associated lung cancer. Lancet 1994; 343: 86
   PubMed Web of Science ®Google Scholar
• Nuorva K., Makitaro R., Huhti E., Kamel D., Vahakangas K., Bloigu R., Soini Y., Paakko P. p53 protein accumulation in lung carcinomas of patients exposed to asbestos and tobacco smoke. Am. J. Resp. Crit. Care Med. 1994; 159: 528
   Google Scholar
• Dosaka-Akita H., Shindoh M., Fujino M., Kinoshita I., Akie K., Katoh M., Kawkami Y. Abnormal expression in human lung cancer is associated with histologic subtypes and patient smoking history. Am. J. Clin. Pathol. 1994; 102(5)660
   PubMedGoogle Scholar
• Wang X., Christiani D. C., Wiencke J. K., Fischbein M., Xu X., Cheng T. J., Mark E., Wain J. C., Kelsey K. T. Mutations in thep53 gene in lung cancer are associated with cigarette smoking and asbestos exposure. Cancer Epid. Biom. Prev. 1995; 4: 543
   PubMed Web of Science ®Google Scholar
• Ryberg D., Kure E., Lystad S., Skaug V., Stangeland L., Mercy I., Borresen A. L., Haugen A. P53 mutations in lung tumors: relationship to putative susceptibility markers for cancer. Cancer Res. 1994; 54: 1551
   PubMed Web of Science ®Google Scholar
• Sozzi G., Miozzo M., Donghi R., Pilotti S., Cariani C. T., Pastorino U., Delia Porta G., Pierotti M. A. Deletions of 17p andp53 mutations in preneoplastic lesions of the lung. Cancer Res. 1992; 52: 6079
   PubMed Web of Science ®Google Scholar
• Walker C., Robertson L. J., Myskow M. W., Pendleton N., Dixon G. R. p53 expression in normal and dysplastic bronchia] epithelium and in lung carcinomas. Br. J. Cancer 1994; 70: 297
   PubMedGoogle Scholar
• Kerr K. M., Carey F. A., King G., Lamb D. Atypical alveolar hyperplasia: relationship with pulmonary adenocarcinoma, p53 and c-erbB-2 expression. J. Pathol. 1994; 174: 249
   PubMedGoogle Scholar
• Nuorva K., Soini Y., Kamel D., Autio-Harmainen H., Risteli L., Risteli J., Vahakangas K., Paakko P. Concurrent p53 expression in bronchial dysplasias and squamous cell lung carcinomas. Am. J. Pathol. 1993; 142(3)
   PubMedGoogle Scholar
• Fontanini G., Vignata S., Bigini D., Merlo G. R., Ribecchini A., Angeletti C. A., Basolo F., Pingitore R., Bevilacqua G. Human non-small cell lung cancer: p53 protein accumulation is an early event and persists during metastatic progression. J. Pathol. 1994; 174: 23
   PubMed Web of Science ®Google Scholar
• Kawajiri K., Watanbe J., Eguchi H., Hayashi S. Genetic polymorphims of drug-metabolizing enzymes and lung cancer susceptibility. Pharmacogenetics 1995; 5: S70
   PubMedGoogle Scholar
• Kawajiri K., Nakachi K., Imai K., Watanabe J., Hayashi S. I. Germ line polymorphism of p53 andCYP1A1 genes involved in human lung cancer. Carcinogenesis 1993; 14(6): 1085
   Google Scholar
• Jin X., Wu X., Roth J. A., Amos C. I., King T. M., Branch C., Honn S. E., Spitz M. R. Higher lung cancer risk for younger African-Americans with the Pro/Prop53 genotype. Carcinogenesis 1995; 16(9): 2205
   Google Scholar
• Birgander R., Sjalander A., Rannug A., Alexandrie A. K., Sundberg M. I., Seidegard J., Tornling G., Beckman G., Beckman L. P53 polymorphisms and haplotypes in lung cancer. Carcinogenesis 1995; 16(9)2233
   PubMedGoogle Scholar
• Sasche R., Murakami Y., Shiraishi M., Hayashi K., Sekiya T. DNA aberrations at the retinoblastoma gene loci in human squamous cell carcinomas of the lung. Oncogene 1994; 9(1)39
   PubMedGoogle Scholar
• Dean D. C., Weintraub S. J., Holtzman M. J. A molecular switch between lung development and cancer: is the tumor suppressor Rb turned on during bronchial epithelial cell differentiation and turned off in small cell lung cancer. Am. J. Respir. Cell Mol. Biol. 1994; 11: 249
   PubMedGoogle Scholar
• Hensel C. H., Hsieh C. L., Gazdar A. F., Johnson B. E., Sakaguchi A. Y., Naylor S. L., Lee W. H., Lee E. Y. Altered structure and expression of the human retinoblastoma susceptibility gene in small cell lung cancer. Cancer Res. 1990; 50: 3067
   PubMed Web of Science ®Google Scholar
• Livingston D. M., Kaelin W., Chittenden T., Qin X. Structural and functional contributions to the Gl blocking action of the retinoblastoma protein. Br. J. Cancer 1993; 68: 264
   PubMedGoogle Scholar
• Ookawa K., Shiseki M., Takahashi R., Yoshida Y., Terada M., Yokota J. Reconstitution of the Rb gene suppresses the growth of small-cell lung carcinoma cells carrying multiple genetic alterations. Oncogene 1993; 8(8)2175
   PubMedGoogle Scholar
• Hiyama K., Ishioka S., Shirotani Y., Inai K. Alterations in telomeric repeat length in lung cancer are associated with loss of heterozygosity in p53 and Rb. Oncogene 1995; 10(5)937
   PubMedGoogle Scholar
• Shapiro G. I., Edwards C. D., Kobzik L., Godleski J., Richards W., Sugarbaker D. J., Rollins B. J. Reciprocal Rb inactivation and p16INK expression in primary lung cancers and cell lines. Cancer Res. 1995; 55(3)505
   PubMed Web of Science ®Google Scholar
• Otterson G. A., Kratzke R. A., Coxon A., Kim Y. W., Kaye F. J. Absence of p16INK4 protein is restricted to the subset of lung cancer lines that retains wild-type Rb. Oncogene 1994; 9(11)3375
   PubMedGoogle Scholar
• Reissman P. T., Koga H., Takahashi R., Figlin R. A., Holmes E. C., Piantadosi S., Cordon-Cardo C., Slamon D. J. Inactivation of the retinoblas toma susceptibility gene in non-small cell lung cancer. Oncogene 1993; 8(7)1913
   PubMedGoogle Scholar
• Clements N. C., Nelson M. A., Wymer J. A., Savage C., Aguirre M., Garewal H. Analysis of k-ras gene mutations in malignant and nonmalignant endobronchial tissue obtained by fiberoptic bronchoscopy. Am. J. Respir. Crit. Care. Med. 1995; 152: 1374
   PubMedGoogle Scholar
• Mills N. E., Fishman C. L., Scholes J., Anderson S. E, Rom W. N., Jacobson D. R. Detection of k-ras oncogene mutations in bronchoalveolar lavage fluid for lung cancer diagnosis. J. Natl. Cancer Inst. 1995; 87(14): 1401
   Google Scholar
• Rothman N., Stewart W. F., Schulte P. A. Incorporating biomarkers into cancer epidemiology: a matrix of biomarker and study design categories. Cancer Epid. Biom. Prev. 1995; 4: 301
   PubMedGoogle Scholar
• Schulte P. A. Biomarkers in epidemiology: scientific issues and ethical implications. Environ. Health Persp. 1992; 98: 143
   PubMedGoogle Scholar
• Tockman M. S., Gupta P. K., Pressman N. J., Mulshine J. L. Considerations in bringing a cancer biomarker to clinical application. Cancer Res. 1992; 52(Suppl.)2711s
   Google Scholar
• Overview: NCI workshop on investigational strategies for detection and intervention in early lung cancer. Cancer Res. 1992; 52: 2639s, (SuppL)
   Google Scholar
• Hirvonen A. Genetic factors in individual responses to environmental exposures. J. Occ. Environ. Med. 1995; 37(1)37
   PubMedGoogle Scholar
• Vineis P., Caporaso N. Tobacco and cancer: epidemiology and the laboratory. Environ. Health Persp. 1995; 103(2)156
   PubMedGoogle Scholar
• Birrer M. J. Translational research and epithelial carcinogenesis: molecular diagnostic assays now — molecular screening assays soon. J. Natl. Cancer Inst. 1995; 87(14)1041
   PubMedGoogle Scholar
• Hasday J. D., McCrea K. A. Inherited predisposition to lung cancer. Occ. Med. State of the Art Reviews 1992; 7(2)227
   PubMedGoogle Scholar
• Raunio H., Pelkonen O. Genetic factors in the activation and inactivation of chemical carcinogens. Drugs, Diet and Disease. I. Mechanistic Approaches to Cancer, Ioannides. Ellis Horwood Ltd, New York 1995; 229
   Google Scholar
• Parke D. V. The cytochromes P450 and mechanisms of chemical carcinogenesis. Environ. Health Persp. 1994; 102(10)852
   PubMedGoogle Scholar
• Soderkvist P., Axelson O. On the use of molecular biology data in occupational and environmental epidemiology. J. Occ. Environ. Med. 1995; 37(1)84
   PubMedGoogle Scholar
• Boers J. E., Ten Velde G. P. M., Thunnisen B. J. M. P53 in squamous metaplasia: a marker for risk of respiratory tract carcinoma. Am. J. Respir. Crit. Care Med. 1996; 153: 411
   PubMed Web of Science ®Google Scholar
• Suzuki H., Takahashi T., Kuroishi T., Suyama M., Ariyoshi Y., Takahashi T., Ueda R. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking. Cancer Res. 1992; 52: 734
   PubMed Web of Science ®Google Scholar
• Horsmans Y., Desager J. P., Harvengl C. Is there a link between debrisoquine oxidation phenotype and lung cancer susceptibility. Biomed. Pharmacother. 1991; 45: 359
   PubMed Web of Science ®Google Scholar
• Kerb R., Brockmoller J., Drakoulis N. CYP2D6. and glutathioneS-transferase class mu as host factors of lung cancer susceptibility. J. Basic Clin. Physiol. Pharmacol. 1992; 3: 131
   Google Scholar
• Pezzella F., Turley H., Kuzu I., Tungekar M. F., Dunhill M. S., Pierce C. B., Harris A., Gatter K. C., Mason D. Y. bcl-2 protein in non-small cell lung carcinoma. N. Engl. J. Med. 1993; 329: 690
   PubMed Web of Science ®Google Scholar
• Kitagawa Y., Wong F., Lo P., Elliot M., Verburgt L. M., Hogg J. C., Daya M. Overexpression of bcl-2 and mutations in p53 and k-ras in resected human non-small cell lung cancers. Am. J. Respir. Cell Mol. Biol. 1996; 15: 45
   PubMedGoogle Scholar
• Dosaka-Akita H., Akie K., Hiroumi H., Kinoshita I., Kawakami Y., Murakami A. Inhibition of proliferation by L-myc antisense DNA for the translational initiation site in human small cell lung cancer. Cancer Res. 1995; 55(7)1559
   PubMedGoogle Scholar
• Higashiyama M., Doi O., Kodama K., Yokouchi H., Tateishi R. High prevalence of bcl-2 oncoprotein expression in small cell lung cancer. Anticancer Res. 1995; 15(2)503
   PubMedGoogle Scholar
• Reeve J. G, Xiong J., Morgan J., Bleehen N. M. Expression of apoptosis-regulatory genes in lung tumor cell lines: relationship to p53 expression and relevance to acquired drug resistance. Br. J. Cancer 1996; 73(10)1193
   PubMedGoogle Scholar
• Murata M., Tagawa M., Kimura M., Kimura H., Watanabe S., Saisho H. Analysis of a germ line polymorphism of the p53 gene in lung cancer patients; discrete results with smoking history. Carcinogenesis 1996; 17(2)261
   PubMedGoogle Scholar
• Devereux T. R., Taylor J. A., Barrett J. C. Molecular mechanisms of lung cancer. CHEST 1996; 109(3), Suppl, 14S
   PubMedGoogle Scholar
• Gariboldi M., Manenti G., Canzian F., Falvella F. S., Radice M. T., Pierotti M. A., Della Porta G., Binelli G., Dragani T. A. A major susceptibility locus to murine lung carcinogenesis maps on chromosome 6. Nature Genet. 1993; 3(2)132
   PubMedGoogle Scholar
• Devereux T. R., Wiseman R. W., Kaplan N., Garren S., Foley J. F., White C. M., Anna C., Watson M. A., Patel A., Jarchow S. Mammalian Genome 1994; 5(12)749
   PubMedGoogle Scholar
• Festing M., Yang A., Malkinson A. M. At least four genes and sex are associated with susceptibility to urethane-induced pulmonary adenomas in mice. Genet. Res. 1994; 64: 99
   PubMed Web of Science ®Google Scholar
• Greenblatt M. S., Bennett W. P., Hollstein M., Harris C. C. Mutations in thep53 tumor suppressor gene: clues to cancer etiology and molecular pathogenesis. Cancer Res. 1994; 54: 4855
   PubMed Web of Science ®Google Scholar
• Kamb A., Gruis N. A., Weaver-Feldhaus J., Liu Q., Harslunan K., Tavtigan S. V., Stockert E., Day R. S. 3rd, Johnson, B. E., and Skolnick, M. H., A cell cycle regulator potentially involved in genesis of many tumor types. Science 1994; 264(5157)436
   PubMedGoogle Scholar
• Cairns P., Mao L., Merlo A., Lee D. J., Schwab D., Eby Y., Tokino K., Van der Riet P., Blaugrand J. E., Sidransky D. Rates of p16 (MTS1) mutations in primary tumors with 9p loss (letter). Science 1994; 265(5170)415
   PubMedGoogle Scholar
• Serrano M., Hannon G. J., Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 1993; 366: 704
   PubMed Web of Science ®Google Scholar
• Hannon G. J., Beach D. p15INK4B is a potential effector of TGF-β-induced cell cycle arrest. Nature 1994; 371: 257
   PubMed Web of Science ®Google Scholar
• Rosvold E. A., McGlynn K. A., Lustbader E. D., Buetow K. H. Identification of an NAD(P)h:quinone oxidoreductase polymorphism and its association with lung cancer and smoking. Pharmacogenetics 1995; 5: 199
   PubMedGoogle Scholar
• Nelson M. A., Wymer J., Clements N. Detection of k-ras gene mutations in non-neoplastic lung tissue and lung cancers. Cancer Letters 1996; 103: 115
   PubMedGoogle Scholar
• Westra W. H., Baas I. O., Hruban R. H., Askin F. B., Wilson K., Offerhaus G. J. A, Slebos R. J. C. K-ras oncogene activation in atypical alveolar hyperplasias of the human lung. Cancer Res. 1996; 56: 2224
   PubMed Web of Science ®Google Scholar
• Grafstrom R. C., Pegg A. E., Trump B. F., Harris C. C. O6-alkylguanine-DNA alkyltransferase activity in normal human tissues and cells. Cancer Res. 1984; 44: 2855
   PubMed Web of Science ®Google Scholar
• Vahakangas K., Trivers G. E., Plummer S., Hayes R. B., Krokan H., Rowe M., Swarz R. P., Yeager H., Jr., Harris C. C. O6-methylguanine-DNA methyltransferase and uracil DNA glycosylase in human broncho-alveolar lavage cells and peripheral blood mononuclear cells from tobacco smokers and non-smokers. Carcinogenesis 1991; 12: 1389
   PubMed Web of Science ®Google Scholar
• Sugimura H., Caparoso N. E., Hoover R. N., Modali R., Resau J., Trump B. F., Lonergan J. A., Krontiris T. G., Mann D. L., Weston A., Harris C. C. Association of rare alleles of the Harveyras protooncogene locus with lung cancer. Cancer Res. 1990; 50: 1857
   PubMed Web of Science ®Google Scholar
• Takahashi T., Nau M. M., Chiba I., Birrer M. J., Rosenberg R. K., Vincour M., Levitt M., Pass H., Gazdar A. F., Minna J. D. p53: a frequent target for genetic abnormalities in lung cancer. Science 1989; 246: 491
   PubMed Web of Science ®Google Scholar
• Nigro J. M., Baker S. J., Preisinger A. C., Jessup J. M., Hostetter R., Cleary K., Bigner S. H., Davidson N., Baylin S., Devilee P., Glover T., Collins F. S., Weston A., Modali R., Harris C. C., Vogelstein B. Mutations in thep53 gene occur in diverse human tumor types. Nature 1989; 342: 705
   PubMed Web of Science ®Google Scholar
• Takeshima Y., Seyama T., Bennett W. P., Akiyama M., Tokuoka S., Inai K., Mabuchi K., Land C. E., Harris C. C. p53 mutations in lung cancers from non-smoking atomic-bomb survivors. Lancet 1993; 342: 1520
   PubMed Web of Science ®Google Scholar
• Vahakangas K. H., Samet J. M., Metcalf R. A., Welsh J. A., Bennett W. P., Lane D. P., Harris C. C. Mutations ofp53 andras genes in radon-associated lung cancer from uranium miners. Lancet 1992; 339: 576
   PubMed Web of Science ®Google Scholar
• Okamoto A., Demetrick D. J., Spillare E. A., Hagiwara K., Hussain S. P., Bennett W. P., Forrester K., Gerwin B., Serrano M., Beach D. H., Harris C. C. Mutations and altered expression of genes regulating the cell cycle G1 checkpoint in human cancer. Proc. Natl. Acad. Sci, U.S.A. 1994; 91: 11045
   PubMed Web of Science ®Google Scholar